Physician profile
Allyson Lancaster
NPI 1083968648
$2,333.21
in general payments reported to CMS, 2019-2025
27 companies · $540 in 2025
The $540 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $300 · 2022: $249 · 2023: $635 · 2024: $609 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,784.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $752.22 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $364.60 | 2021-2025 | |
| Pfizer INC. | $207.75 | 2023-2025 | |
| Lilly USA, LLC | $170.82 | 2021-2024 | Mounjaro |
| Intuitive Surgical, INC. | $94.88 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $93.00 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Exact Sciences Corporation | $73.32 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amgen INC. | $66.26 | 2021-2025 | Evenity, Prolia |
| Glaxosmithkline, LLC. | $62.50 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.45 | 2021-2023 | Trulance, Xifaxan |
| Astellas Pharma US INC | $40.95 | 2021-2023 | Veozah |
| Corium, LLC | $32.21 | 2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $29.28 | 2021-2023 | Trintellix |
| Eisai INC. | $29.16 | 2021 | |
| Merck Sharp & Dohme LLC | $28.14 | 2022-2024 | Vaxneuvance, Capvaxive, Gardasil 9 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $27.84 | 2023 | Vyepti |
| Axsome Therapeutics, INC. | $26.32 | 2025 | Auvelity |
| Sanofi-Aventis U.S. LLC | $24.84 | 2022 | |
| Upsher-Smith Laboratories LLC | $21.77 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $21.48 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $19.70 | 2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $17.38 | 2022 | |
| Kaleo, INC. | $16.36 | 2022 | |
| Noven Therapeutics, LLC | $16.13 | 2023 | Xelstrym |
| Antares Pharma, INC. | $15.69 | 2024 | Xyosted |
| Amarin Pharma, INC. | $14.83 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allyson Lancaster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.